

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of inhibiting angiogenesis in humans and animals which comprises administering a therapeutically effective amount of a simmondsin, stereoisomeric forms, racemic mixtures, ~~metabolites~~, esters or salts thereof to the human or animal in need thereof.


2. (Previously presented) The method according to claim 1, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.

3. (Currently amended) The method according to claim 1, whereby said simmondsin is selected from the group consisting of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4,5-dimethylsimmondsin, stereoisomeric forms, racemic mixtures, ~~metabolites~~, esters or salts thereof, and any mixtures thereof.

4. (Previously presented) The method according to claim 1 wherein said esters are ferulates.

5. (Previously presented) The method according to claim 1, whereby said simmondsin is selected from the group consisting of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.

6. (Currently amended) A method for inhibiting angiogenesis in humans and animals comprising administering to the human or animal in need thereof a therapeutically effective amount of a compound having general formula (I)



Formula (I)

and stereoisomeric forms, racemic mixtures, ~~metabolites~~, esters, salts, or mixtures thereof,

wherein R_4 and R_5 are independently selected from the group consisting of oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkylloxycarbonyl, alkylthiocarbonyl, alkanoyl, cycloalkyl, cycloalkylalkyl, cycloalkylcarbonyl, cycloalkylalkanoyl, cycloalkylthiocarbonyl, cycloalkylalkoxy, cycloalkylalkoxythiocarbonyl, cycloalkylthioalkyl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, cycloalkylcarbonyloxyalkyl, silyloxyalkyl, aryl, aralkyl, arylalkenyl, arylcarbonyl, aryloxy, aryloxyalkyl, arylthioalkyl, haloalkyl, hydroxyalkyl, aralkanoyl, aroyl, aryloxyalkyl, arylthioalkyl, haloalkyl, hydroxyalkyl, aralkanoyl, aroyl, aryloxyalkyl, arylthioalkyl, haloalkyl, hydroxyalkyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoate, aminoalkyl, $CR^6=NR^7$ and $CR^6=N(OR^7)$, with R^6 and R^7 being independently selected from the group consisting of hydrogen, hydroxyl, alkyl, aryl, alkenyl, alkynyl, aminoalkyl, aminoaryl, alkylcarbonylamino, arylcarbonylamino, alkylthiocarbonylamino and arylthiocarbonylamino; and

wherein R_3 , R_2' , R_3' , R_4' , and R_6' are independently selected from the group consisting of hydroxyl and an ester.

7. (Previously presented) The method according to claim 6, wherein R_4 and R_5 are independently selected from the group consisting of oxo, hydrogen, hydroxyl, alkyl, alkenyl, alkynyl, alkyloxy, alkyloxyalkyl, alkylthioalkyl, alkylloxycarbonyl, alkylthiocarbonyl, alkanoyl, alkylcarbonyloxyalkyl, arylcarbonyloxyalkyl, silyloxyalkyl, haloalkyl, hydroxyalkyl, carboxyl, formyl, alkenylcarbonyl, alkynylcarbonyl, cyano, aminocarbonyl, aminoalkanoate, aminoalkyl, and wherein R_3 , R_2' , R_3' , R_4' , and R_6' are independently selected from the group consisting of hydroxyl and an ester.

8. (Previously presented) The method according to claim 6, wherein R_4 and R_5 are independently selected from the group consisting of hydroxyl, alkyl, and alkyloxy, and wherein R_3 , R_2' , R_3' , R_4' , and R_6' are independently selected from the group consisting of hydroxyl and an ester.

9. (Previously presented) The method according to claim 6, wherein R_4 and R_5 are independently selected from the group consisting of hydroxyl, and $-OCH_3$, and wherein R_3 , R_2' , R_3' , R_4' , and R_6' are independently selected from the group consisting of hydroxyl and an ester.

10. (Previously presented) The method according to claim 6, wherein said ester is a ferulate.

11. (Previously presented) The method of claim 1, wherein the human or animal has an angiogenesis-related disease.

12. (Previously presented) The method according to claim 11, whereby said simmondsin naturally occurs in jojoba and is comprised within jojoba flour or a jojoba extract.

13. (Previously presented) The method according to claims 11, whereby said simmondsin is selected from the group consisting of 4-desmethylsimmondsin, 5-desmethylsimmondsin, 4,5-didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, 4,5-didesmethylsimmondsin-2'-ferulate, 4,5-dimethylsimmondsin-2'-ferulate, and any mixtures thereof.

14. (Previously presented) The method of claim 6, wherein the human or animal has an angiogenesis-related disease.

15. (Previously presented) A simmondsin having general formula (I), as defined in claim 6, with the exception of 4,5-dimethylsimmondsin and 4,5-dimethylsimmondsin-2'-ferulate.

16. (Previously presented) A method of treating disease in humans and animals comprising administering a therapeutically effective amount of 4-desmethylsimmondsin, 5-

desmethylsimmondsin, 4,5 didesmethylsimmondsin, 4-desmethylsimmondsin-2'-ferulate, 5-desmethylsimmondsin-2'-ferulate, and 4,5-didesmethylsimmondsin-2'-ferulate, as a medicament to the human or animal in need thereof.

17. (Previously presented) A pharmaceutical composition comprising a polar extract from jojoba flour and one or more solid or liquid pharmaceutical excipients and/or auxiliaries.

18. (Previously presented) A method for inhibiting angiogenesis in humans and animals comprising administering a therapeutically effective amount of jojoba flour or an extract from jojoba flour to the human or animal in need thereof.

19. (Previously presented) The method of claim 18, wherein the human or animal has an angiogenesis-related disease.

20. (Currently amended) A pharmaceutical composition ~~for inhibiting angiogenesis or for treating angiogenesis-related diseases~~ comprising a therapeutically effective amount of a compound as defined in claim 6 with the exception of 4,5-dimethylsimmondsin and 4,5-dimethylsimmondsin-2'-ferulate and a pharmaceutically acceptable excipient.

21. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied orally.

22. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied parentally.

23. (Currently amended) ~~Pharmaceutical~~ The pharmaceutical composition according to claim 20, wherein said pharmaceutical composition is formulated to be applied topically.

24-25. (Cancelled)